These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 31424674)

  • 1. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
    Zhao C; Ma SPZCY
    J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
    Zhang X; Lin X; Qiu H; Peng Z
    J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CalliSpheres
    Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
    Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
    Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
    Front Oncol; 2021; 11():793581. PubMed ID: 35127501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of chemoembolization with CalliSpheres
    Liang B; Xiang H; Ma C; Xiong B; Ma Y; Zhao C; Yao Y; Zhang Z; Chen C; Li H; Long Q; Zhou J; Luo C; Qiu H; Hu H; Zhao H; Zhou G; Zheng C
    Cancer Manag Res; 2020; 12():941-956. PubMed ID: 32104076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
    Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
    Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
    Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of CalliSpheres
    Jin B; Gu Y; Xi S; Liu X; Wu X; Wang X; Li G
    Scand J Gastroenterol; 2024 Sep; 59(9):1087-1092. PubMed ID: 39154241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.